Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE - 23/12/17
, Claire Masson b, Jean-Paul Eschard a, Thomas Bardin c, Arnaud Constantin d, Loïc Le Dantec e, Christian Marcelli f, Aleth Perdriger g, Claire Scotto Di Fazano h, Daniel Wendling i, Jean Sibilia j, Jacques Morel k, Jean-Hugues Salmon aBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
Assess the frequency of paradoxical reactions encountered in daily practice under tocilizumab, using the REGATE (Registry-RoActemra) registry. The secondary objectives were to determine the type of paradoxical reaction and the consequences of these reactions.
Methods |
The REGATE registry is an independent prospective registry, promoted by the French Society of Rheumatology, consisting of patients treated with tocilizumab for rheumatoid arthritis. The paradoxical reaction was retained if it was a paradoxical precipitation of a condition for which tocilizumab was indicated, if tocilizumab was being used for an alternative indication, and if it appeared after at least one tocilizumab infusion.
Results |
Among the 1491 patients included with at least one follow-up visit (3429 patient-years), a paradoxical reaction occurred in 9 patients (0.60% of patients; 2.62/1000 patient-years). These were 7 de novo pathologies (3 vasculitis, 3 uveitis, 1 lupus) and 2 exacerbations of pre-existing conditions (1 vasculitis, 1 lupus). Permanent discontinuation of tocilizumab was chosen for 5 patients.
Conclusions |
In the REGATE registry, the occurrence of paradoxical reactions in patients treated with tocilizumab was rare.
Le texte complet de cet article est disponible en PDF.Keywords : Tocilizumab, Paradoxical reactions, Rheumatoid arthritis, Vasculitis, Lupus, Uveitis
Plan
Vol 85 - N° 1
P. 53-57 - janvier 2018 Retour au numéro
Article précédent
- New structural formats of therapeutic antibodies for rheumatology
- Christophe Dumet, Jérémy Pottier, Valérie Gouilleux, Hervé Watier
- Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial
- Francis Berenbaum, Thao Pham, Pascal Claudepierre, Thibault de Chalus, Jean-Michel Joubert, Carine Saadoun, Lionel Riou França, Bruno Fautrel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?